Accelerated development of anticancer drugs

Accelerated development of anticancer drugs

October 23, 2017 Source: Economic News

Recently, Shanghai Pharmaceutical Group Co., Ltd. and its wholly-owned subsidiary Shanghai Jiaolian Pharmaceutical Development Co., Ltd. jointly developed a recombinant anti-HER2 humanized monoclonal antibody composition for injection, which was approved by the State Food and Drug Administration. Approval.

 
In recent years, more and more domestic listed pharmaceutical companies have joined the research and development of innovative drugs such as anti-tumor drugs. Among the A-share listed companies, a number of listed companies such as Hengrui Medicine, Yiyi Pharmaceutical, Changsheng Bio, Kelun Pharmaceutical, Shijiazhuang Pharmaceutical Co., Ltd. and Beida Pharmaceutical have been placed in the field of cancer, related to the concept of “anti-cancer”. The company is close to 60 companies.

 
Because cancer is fierce, all parties are making every effort to promote the development of anticancer drugs in China.

 
After reviewing the report, the reporter found that although the number of new types of new drugs independently developed by China is limited, many listed pharmaceutical companies have already developed research and development of cancer drugs, and have made many breakthroughs in clinical trials. Recently, the Chinese Academy of Sciences academician He Jie publicly said that China's cancer clinical and research have made great progress, and the current cancer big data platform should be accelerated.
 

On October 11, Fu Daotian, vice president of Livzon Group, said in an interview that although China's anticancer drug industry started late, the drug development rate is very fast.
 

Multiple listed companies layout
 
On October 12, Shanghai Pharmaceutical announced that recently Shanghai Pharmaceutical Group Co., Ltd. and its wholly-owned subsidiary Shanghai Jiaolian Pharmaceutical Development Co., Ltd. jointly developed a recombinant anti-HER2 humanized monoclonal antibody composition for injection. Approval of the drug clinical trial issued by the State Food and Drug Administration.
 

The drug is a novel human recombinant monoclonal antibody preparation intended for HER2-positive metastatic breast cancer, and neoadjuvant therapy for HER2-positive breast cancer.

 
According to reports, Shanghai Pharmaceutical started the project in September 2013 and completed preclinical research in August 2016. Up to now, the drug has invested a total of about 92 million yuan in research and development. It is worth mentioning that there are two similar drugs of the same target at home and abroad. One is Roche's trastuzumab, which has a global sales of US$6.85 billion in 2016. The second is the Pert- s of Perot Pharmaceuticals. Monoclonal antibody, last year's global sales of 1.87 billion US dollars.

 
The reporter found out that in recent years, more and more domestic listed pharmaceutical companies have joined the research and development of innovative drugs such as anti-tumor drugs. Among the A-share listed companies, a number of listed companies such as Hengrui Medicine, Yiyi Pharmaceutical, Changsheng Bio, Kelun Pharmaceutical, Shijiazhuang Pharmaceutical Co., Ltd. and Beida Pharmaceutical have been placed in the field of cancer, related to the concept of “anti-cancer”. The company is close to 60 companies.

 
As of the first half of this year, Fosun Pharma has 6 monoclonal antibody varieties (11 indications) that have been approved in China, and 2 of them have entered clinical phase III. In the first half of the year, the domestic oncology giant Hengrui Pharmaceutical invested a total of 780 million yuan in research and development, and obtained 9 clinical approvals for innovative drugs and 8 clinical approvals for generic drugs.

 
However, from the current medical treatment status of cancer patients, the access rate of new anti-cancer drugs in China is still behind that of European and American countries. The data show that, unlike the global tumor market, the sub-categories of the Chinese cancer market are growing much faster than the international market, and the market players are still traditional chemotherapy drugs, accounting for 70% of the market. However, in the international market, chemotherapeutic drugs are being phased out, and the development of targeted drugs has become the development trend of global oncology drugs, and the Chinese market will certainly shift to the trend.
 

A large number of emerging research companies emerge
 
Since 2006, the state has intensively introduced a series of support policies in the field of bio-pharmaceuticals. At present, some drugs have entered the stage of clinical trials. “Made in China” is trying to reverse the inherent impression of international counterparts and patients.
 

In April this year, foreign media reported that “China has long been a supplier of cheap raw materials and generic drugs in the world, and is now emerging as a major producer of important new drugs such as biotech drugs. According to the latest US relevant departments Data, in terms of the number of biotherapeutic clinical trials, China is currently ranked second in the world, second only to the United States."
 

According to the report, as of the past decade of 2015, a total of 586 molecules have entered clinical research, 87% are targeted drugs, and more than 500 companies are active in the development of oncology drugs. However, the reporter noted that the influence of Chinese pharmaceutical companies in the international market has been quite limited so far, and pharmaceutical giants such as Roche, AstraZeneca, Bristol-Myers, Merck and Pfizer are in the top five.
 

Compared with some traditional enterprises focusing on chemical drugs and proprietary Chinese medicines, some emerging research companies have sprung up. Under the trend of policy reforms in the country to accelerate the innovation of pharmaceutical companies, these companies are also actively carrying out innovative drug research and development. He Jie also said that in recent years, China has arranged a large amount of fiscal expenditure every year to support the early treatment of cancer. The research and development of new drugs for malignant tumors has also received a large amount of research funding support, and China's cancer clinical and research have made great progress.
 

A research and development person from a listed pharmaceutical company in Guangdong told reporters that overall, the talents of China's pharmaceutical industry have changed a lot. Many foreign experts who work in life sciences, especially in the field of medicine, have returned to China in recent years. These people return to China. Directly led to the development of new drug research and development industry. "Now the domestic research and development of new drugs is dominated by Dr. Haigui, and some even bring back their teams in the United States. This is a good phenomenon. In fact, there are still many companies doing new drug research and development, but because of the whole The cycle is long and has not seen results."

 
Fu Daoda has worked in the United States for more than 30 years. He has served as a senior executive of a well-known pharmaceutical company and is currently a special expert in the “Thousand Talents Program”. He is full of hope for the future of biomedicine in China. "The whole bio-anticancer drug industry, China has entered 20 years later than European and American countries; but because of the lessons learned from the past and the lack of detours, China's drug development rate is very fast, probably two in developed countries. Double."

 
According to the report, the global compound growth rate of the oncology drug market in the past five years as of 2015 was 7.4%, and the compound annual growth rate of cancer therapeutic drugs was 9.8%. It is estimated that by 2020, the global oncology drug market will exceed 150 billion US dollars, an increase of nearly 50% over the 2015 US$107 billion.
 

Sterile Container

Medical sterile container is a common medical equipment, mainly used for the storage of instruments in the process of packaging, sterilization, transit, storage, etc.

The sterilization box as a whole is made of anodized aluminum, which provides anti-pressure, moisture-proof and dust-proof protection during sterilization, transportation, transit and use. The sterilization container has good sealing performance, and the sealing ring is made of silicone material:. The safety lock device is locked once to avoid misoperation.

Sterile Container,Sterilization Box,sanitizing box,sterilizer box

Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com